Shanghai, China, December 26, 2024 - JW (Shanghai) Therapeutics Co. Ltd. (the "Company" or "JW", together with its connected parties, collectively the "Group"), an independent, and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products has won the 2024 ESG Era Pioneer Award in the CNR Corporate Social Responsibility Case selection activity.
On December 26, 2024, the Corporate Social Responsibility case selection held by CNR was held in Beijing, and JW won the "2024 ESG Era Pioneer Award", which further confirmed the corporate value.
CNR is China's largest comprehensive news website featuring audio information, and is the central key news website and one of the most influential network media in China. The selection of corporate social responsibility cases aims to promote the concept of corporate social responsibility and promote the practice and innovation of corporate social responsibility. The award marks that the company's performance in ESG has been highly recognized by the society.
Mr. Min Liu, Executive Director and Chief Executive Officer of JW
"As a pioneer in the field of cell immunotherapy in China, JW has introduced international cutting-edge technology to benefit Chinese patients. Based on the company's core values of putting patients first, JW actively explores solutions to meet the challenges of commercialization of innovative products, continues to promote the commercialization process of Carteyva®, and strives to improve the accessibility and affordability of products, so that cell immunotherapy can benefit more patients. To reduce the burden on patients, we are taking advantage of the development of China's multi-tiered health insurance system to include Carteyva® in more local governments' supplementary health insurance plans and commercial insurance products. At the same time, we cooperate with various charitable platforms such as public welfare foundations to provide patients with charity funds, social crowdfunding and other assistance."
With rich ESG practice results and perfect strategic layout, JW has won a number of honors in recent years, such as Award for “Annual Responsibility Pioneer” in ESG Trend Forum 2023 held by the Finance Department of NetEase, and Award for “Most Valuable Pharmaceutical and Healthcare Company” in the 8th Zhitong Finance Capital Market Annual Conference. Looking forward to the future, JW will continue to actively respond to the national call for low-carbon green development, guided by the ESG concept, fully implement corporate responsibility, help cell immunotherapy industry upgrading, and continue to lead the future development of innovative medicine in China.
About Relmacabtagene Autoleucel Injection
Relmacabtagene autoleucel injection (abbreviated as relma-cel, trade name for oncology indications: Carteyva®) is an autologous anti-CD19 CAR-T cell immunotherapy product independently developed by JW Therapeutics based on a CAR-T cell process platform of Juno Therapeutics (a Bristol Myers Squibb company). Being the first product of JW Therapeutics, Carteyva® has been approved by the China National Medical Products Administration (NMPA) for three indications, including the treatment of adult patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) after two or more lines of systemic therapy, the treatment of adult patients with follicular lymphoma that is refractory or that relapses within 24 months of second-line or above systemic treatment (r/r FL), and the treatment of adult patients with relapsed or refractory mantle cell lymphoma (“r/r MCL”) after two or more lines of systemic therapy including bruton tyrosine kinase inhibitors (“BTKi”), making it the first CAR-T product approved as a Category 1 biologics product in China. Currently, it is the only CAR-T product in China that has been simultaneously included in the National Significant New Drug Development Program, priority review and breakthrough therapy designations.
About JW Therapeutics
JW Therapeutics (HKEx:2126) is an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products. Since its founding in 2016, JW Therapeutics has built an integrated platform for product development in cell immunotherapy, as well as a product pipeline covering hematologic malignancies, solid tumors and autoimmune diseases. JW Therapeutics is committed to bringing breakthrough and quality cell immunotherapy products and the hope of a cure to patients in China and beyond, and to leading the healthy and standardized development of China’s cell immunotherapy industry. For more information, please visit www.jwtherapeutics.com.
Forward-Looking Statements
The forward-looking statements are based on the management's expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described. Significant risks and uncertainties, include those discussed below and more fully described in Hong Kong Exchanges and Clearing Limited (HKEx) reports filed by the Company. Unless otherwise noted, the Company is providing this information as of the date it publicized, and expressly disclaims any duty to update information contained in the issues and relevant information, or provide any explanation. For detailed information, please visit the company website: www.jwtherapeutics.com/en/forward-looking-statements/.